Cite
HARVARD Citation
Orlowski, R. et al. (n.d.). A phase 2, randomized, double‐blind, placebo‐controlled study of siltuximab (anti‐IL‐6 mAb) and bortezomib versus bortezomib alone in patients with relapsed or refractory multiple myeloma. American journal of hematology. 90 (1), pp. 42-49. [Online].